Aptose Biosciences (APTO)

Susan Pietropaolo Corporate Communications and IR
Dr. William G. Rice Chairman, President and CEO
Dr. Joti Marango SVP, CFO, and Chief Business Officer
Dr. Rafael Bejar SVP and Chief Medical Officer
Ted Tenthoff Piper Sandler
Joe Pantginis H.C. Wainwright
Matt Biegler Oppenheimer
Soumit Roy Jones Research
Matthew Cross Allegiance Global Partners
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.

Good afternoon. My name is Jonathan, and I will be your conference operator today. I would like to welcome everyone to the Aptose Biosciences Conference Call for the Fourth Quarter Ended December 31, 2021. At this time, all participants are in a listen-only mode. After the speakers’ remarks, there will be a question-and-answer session. you. Thank Instructions] [Operator

this to is today’s introduce -- Pietropaolo reminder, would program, recorded. now from ahead. go like your please conference a being call I Susan As host for

Susan Pietropaolo

as these discuss release welcome Jonathan. you, Aptose SEC call website. release results related quarter ended Good press the and ended as XXXX. to financial Thank Aptose to December issued operational and accessible a financial XX, afternoon, are Biosciences news on the conference year well results. fourth The for to filings Earlier related today, Aptose’s

today’s Officer. Joining Rafael and Dr. Chairman, Senior Chief Dr. are Vice on and Marango, Medical and Officer; Bejar, call Rice, Senior Dr. William Joti Officer Business President Vice G. President, President Financial Chief Chief CEO; and

to meaning of and proceed, that call would everyone this during laws. we certain U.S. the include made I forward-looking within will like remind Canadian securities statements statements Before

Dr. date as to the SEDAR forward-looking obligation statements All law. update the of Rice? of the filings. required circumstances regarding are Aptose made of and and is undertakes but Aptose’s involve reflect events are events on assumptions the future known call, and and statements reflect differ date forth and I Aptose’s call could performance achievement call about those that Rice, recent except SEC report this most speak guarantees risks and results, now CEO or not President more stated possible from unknown annual by materially current expectations. Forward-looking these only They or Dr. it and actual of XX-K Form expectations performance, made. performance revise please during to To uncertainties will statements differ set no materially Chairman, they risks, Aptose may Biosciences. from cause turn this to expressed. uncertainties, over and these to the risk learn that factors read actual and as in results after

Dr. William G. Rice

everyone a give programs highlights welcome XXXX, you, outline is and December of recap an anticipate the key we like to a I’ll year-end our ended To call I’d clinical XXXX. fourth a on Susan. you remind to XXXX. of which quarter quick precision in Aptose milestones our and also call, you, kinase treatment and Thank XX, today’s clinical-stage oncology update actions for our status differentiated company, the patients for our highly success. find we that And HMXXXXX Company for drug are hematologic oral foresight, want visibly team’s the today, a stress developing malignancies. progress the of molecules, to few inhibitors luxeptinib. illustrate position in that candidate I about for and upbeat our with you’ll our In

fourth and this we year clinical programs we value-driving before sheet, evaluating This extended runway in the balance essential quarter thought the cash programs. but next well capital year, to runway we beyond even necessary. our programs implemented of focus of company streamline without the a or programs, streamlining strategically value-building year. reprioritization and extend corners, a of the by pipeline which expenses, not process resources needs was First, of value. from updates have goes Through cash to into now to some in for capabilities by and cutting on with believe our potential began we XXXX, XXXX, our strong in series undermining our meticulous last a but And raised carefully

initiated to through to ago, development could for shareholders. or patients, and And and more deliver the lux exposure the improve for Company years now original just such to responses than we because team lux to lux, formulation need a value evaluating formulation GX and GX and molecule. demonstrated as greater humans. formulation believe in formulation of formulation luxeptinib the more we demonstrate we greater opportunity the for we to two as CMC clinic are the potential an improved our active We Second, an move built the recognized and

that more we a as the led refer to just Third, two ago asset or to XXX, licensing years initiated of HMXXXXX, deliberate we’ll search it. than

forefront Now, pipeline. XXX has moved to of the our

a took supply. the with clinical demonstrate continues and a effective trial, As overnight, activity, added led to fourth, investigators. our with we well-tolerated XXX to asset And we to increase literally clinical more efforts and XXX and to and advanced derisked clinical patients us control XXX drug pipeline of clinical value before impress available significant even to the proven our rapidly value

amendments clinical number I sites to to approvals. has agent with of also This a and that upcoming fast to of as identify protocol entered of track. lux, now far serve trials the began was doses expansions. for data could acknowledge delivered on on that ahead cohort and expand could XXX populations messaging to as place XXX year our patients expansion recognize That single also AML populations to number and that deliver select more XXX efficacy serve ahead and in expansion effective patients we genotypically AML introduce responses multiple as lux. for increase additional focuses combination because want safety the accelerated is to a that and other to We doses agents the a AML of in enriched done it already

believe prioritize give we formulation. as to GX continue we lux, our assess continue possible in to the want best more the will to succeed mature new we XXX, and chance we to While

to XXXX. we recap begun But place investment know, position take a fruit we Company to our we the forward. our hematologic Collectively, the business we fortunate patient has studies. of very in needs drive having So agents the the approach bullish before will are and malignancies, and disciplined there, for forward-looking, and the how you bear in path the well-differentiated inhibitors data, as run big two in our of go a because maturity we this approach And position we treatment to oral let’s kinase clinical XXXX. picture, in are allow and the the of

Aptose The populations. presented we lux continued participation in Hematology BTK of escalate of the including data or be higher programs with disease the reversal B-cell times both, for successfully in clinical to reductions both acute June, our B-cell on XXXX, delivered may leukemia, dose intrapatient myeloid activity, disease may In in clinical even drug EHA, clear ibrutinib, trials concurrently escalation pretreated reported cancer Association, our a of of of formulation European the cohorts across with to the lux. forced original seek and continue us AML, lux the In activity. low B-cell aggressive escalate solubility, and lux signals During including intermediate of had superior or dose have higher in patient that Reminiscent properties challenged inhibitor, Virtual demonstrate durable different upon that in activity doses AML heavily growth two suggested that multiple dose complete first of encouraging exposures malignancies. patients, AML, tumor delivered that remission. XXXX to which Congress. exposure solubility We negative levels antileukemic longer experienced MRD a cancers, to patient

of patients good escalation AML, parallel significant was made it we call So, B-cell the in timing GX. in which dose progress we in next-generation with formulation, a development that of and malignancies the lux

greater of And to announced solubility administered. our in milligram issues update lux XX-fold up and addressed about lux talk the QX formulation, years. GX the exposure We’ll minutes, drug for a XXXX. working on XXXX now back more formulation a lux to few basis per in delivered but as GX of the preclinical studies, two formulation had in I of original more that the have been to new We we said, than for optimize effectively

describe exclusive relapsed/refractory patients operative of an the complete inhibitory worldwide our minutes. potently AML profile including ERK During has delivered Hanmi a XXXX, trial good to Officer, Bejar, XXX inhibitor with factor ongoing of the new other FLTX, few kinase adverse will myeloid fourth kinases. November, such our mutation quarter mutant Pharmaceutical agreement This into license the lead with and c-KIT the Oral enables kinases kinase JAK/STAT forms and already molecule, Dr. validated FLTX you confer resistance In resistance a delivered suppress XXX, international and AML of as a develop growth Chief in to inhibits is Company clinically Medical commercialize MAP SYK, that as news. JAK agents. to entered as forms X/X pathways we an conferring pathways and kinome that additional we XXX. Phase in and remissions clinical diversity of mutant XXX to in profiles,

release adverse AML populations time. high identify clinical all has the that XXX transplant reported patients the Naval durable investigator Daver the trial. Importantly, us stem patients remissions, of Cancer either MD XXX backgrounds. thereby that mutations, ongoing delivered through CRs, to accelerated oral allowing broad of establish diverse XXX response providing an clinical presentation with relapsed/refractory to delivered with medical Dr. a multiple clinical strikingly genotypic responders, In bridging benefit Daver XXXX, first meaningful for in Center, results potential lead highly in at AML defined activity trial, December with a to over XXX or or promising Dr. for development to from and public Anderson them demonstrated need complete across with unmet genotypically by ASH from cell

and the During with XXX and a clinical the you moment. closely XXXX worked of ensure hear for more investigators to the activities Hanmi smooth we trial about principal transition quarter, will to Aptose, fourth in a

APTO-XXX. announced The the and of runway. to pipeline a to the the XXX XXXX, clinical nonessential took discontinuation and accelerate aware, development followed XXXX any we programs, prioritization most our candidates strength reduce decision steps are and Company’s us lux. of more allows place delivery sites prioritize our focus enrollment resources for of we inhibitors, for of you actionable of of operate in add as that and to to of the other patient As at and efficiently value-driving advanced Collectively, within cash to our our kinome the advance milestones development allows and position also the derisk our devote pipeline clinical expenses, toward end Company to we

development clinical position as first and objectives the year we we’ve XXXX rapid and clear to We with part of be of of the our created during lux for Aptose programs. In I’m for these And execute an we a XXX. the and continue to strategy clinical important expect pleased XXX have and particular, the progress vision for XXXX. advance

for directly Raf? Chief let’s So, Bejar, the have Medical Officer, update Dr. our move XXX. Rafael into

Dr. Rafael Bejar

Bill. you, Thank

myeloid want with dose into combined through venetoclax azacitidine. This series inhibitors. of just to remind study about encompass described escalation in composite differentiates kinase XXX out the in talk or to kinase MAP TPXX, single incomplete cohort. level inhibitor moment of when inhibitor gilteritinib have wild-type both five what the kinase, preclinical AML including one at patients profile we has profile a forms hematologic inhibits the as it I of inhibiting but add includes already mutant This a pathways. an DLTs to highly X downstream kinase pathways, dosing dose plus last completed more X/X also FLTX. and at been treated IDHX inhibitory wild no FLTX and or and just uses effective structure forms group This and a SYK, of But AML array and other tolerated CRCs, clinical XXX XXX, of Phase additional patients which of allows the that the X expand Phase mutations four first as traditional patients with agent you and harboring among a signaling dose ITD activity thus have X kinase in patients level us CRi been very co-mutations. and of XXX domain unqualified than or complete RAS only translated our FLTX and the adverse XXX diverse patients CRs other all complete is with JAK/STAT recovery of it in milligrams. impressive of AEs tested. a our complete oncogenic groups from In to refractory take Let’s remission FLTX which with highly we XX-milligram patients a is remissions reported a diverse the call, or other multiple kinome already and NPMX, well the ERK Most strong to inhibitor, to protocol, superior has type mild FLTX date antileukemic a of patients, the far, with tyrosine as known delivering with trial remissions,

midostaurin. FLTX-ITD and complete remission bridge hope, This a would mutant for previously cell which increasingly patient the patients includes remission a transplant. mutations, common, the subgroup accelerated and achieve one CRi. need with approval. that a unmet and carried Among One complete NRAS is inhibitors, treated with could co-mutation, FLTX one population two stem FLTX approved they an serve As with to refractory treatment and ideal gilteritinib patients at this experienced and FLTX is medical highly

respond mutation bridge therapy remission transplant. TPXX second were The treatment two and And with this bridge third Patients carried NPMX by One also gilteritinib. transplant. an with to responses to that had patient after This in wild-type FLTX stem also a FLTX a background quickly do. and presented highly a co-mutations the failed relapse patient if both, mutational complex complete a Then tyrosine complete remission there even stem with of patient patient genotype, a achieved wild-type a defined to with and typically XXX they therapy FLTX a a and with not AML mutation prior highly patients FLTX-ITD or harbored achieved and karyotype. remission. with cell agent complete cell or a adverse and kinase experienced a complete single mutation do also midostaurin adverse domain

of was breadth and that While a This speaks transplant on a and complete patient that unfit XXX remission patient the duration exceeded of. enjoyed response XXX for is this year. durability the a one to considered to achieved age, example capable stem due cell

to patient carry Another also a also complete achieving was cell the a mutation, a IDHX after taken with wild-type transplant. remission, FLTX stem and

And curative arm early observed dose in and clinical with CRi benefit durable additional TPXX XXX-milligram complete complete to the report out And with mentioned completed a year. patient milligrams the the I we’ve a happy significant experienced with was X lasting very fact, XX mutation transplant patient a recently patients In or that of cohort data, that remissions very than report of relapsed to one a remission stem we the bridged with who Cri, more from I’m a to the for cell X transplantation, achieved potentially either happy expansion allogeneic an were enrollment AML. ineligible CR procedure.

population do these to in we EHA of dose in not a providing that list abnormalities details multiple concurrently are time, levels. [indiscernible]. the milligram lowest treat. illustrate to patients It’s genotypes these antileukemic These cohort of simply focused level have patients also additional grow on the breadth population as brisk, expansion. we the very trial, this our identify respond to strong treatable observations remissions? here appears and moving data helped and with of While responding to genotypes to to are appear populating data now the the AML our further adverse theme because are future patient XXX AML this as responding has this dose XXX, to are of at the Why to dose at activity dose We And been In important gene specifics these us patients our our mutations at that takeaway instead carry the uncover on for that MLL XXX-milligram would this that of expanding of communicate messages drug. important plan demonstrated XXX. expansions of this XXX. to And be key disclose is going the but be we genetic of a we with is relapsed/refractory is June, enrollment including dose

our dose of clinical to doses encouraged table. identified trials. our In highly could full XXX clinical milligrams have doses, require are for leave well-tolerated of with set go-forward continue some make challenging we which are we serve into take in mutations, short, of by the said, That higher as we may seeing the respond. activity as We we and XXX XX to any adverse what of potential don’t the we expansion patients inactive prepare want to milligrams. XXX two that on It and next unexplored trials sure we exploring

eye registrational we We expansion may continue to patient the with select dose defined to trials dose explore towards the so fixed an AML genetically XXX-milligram accelerated expansion dose, optimal population initiate pathways. select and

messages AML level, early activity an shown To So across dose recap genotypes. major now, XXX key has broad for let’s at summarize, several XXX.

unmet that While with genotypes effective expand minimum believe intent marketing -- label dose into genotype-agnostic need we’ve we a already later and been potential for profile, can to accelerated an high approvals we trials. XXX the leverage take several can with additional genotypes. expansion therapeutically to development clinical identified represents A has leverage to identified

for However, us well optimal the because to cohorts we ongoing of the Based are in development a and these includes trial and as to on date the difficult favorable This enriched to registration-directed single later treat date, safety higher the allow expansion dose as genetically agent dose. from of new expansion profile a that particularly studies XXX and will this XXX. are expansions agent for single doses seen across exploring expansions, patients to lessons set as strong year. AML planning we signals of a already subpopulations select diverse

single studies into our to are treatment. planning addition complement move earlier In of and that XXX allow lines therapies studies, to existing would agent combination we


a to review luxeptinib. of quick on Now,

a in tumor being reductions, dose as over activity, observed both tumor multiple a at cycles exposure Just vivo giving known at follicular patients CLL is both toxicities, a dosed associated with avoids known AML, Target and studies. with FLTX dependent diffuse antitumor in and and XXX malignancies. Phase clinical lymphoma, demonstrated lymphoid BTK including milligrams apoptosis only been In XXX engagement reminder, that triggered large have is lux therapeutic BID currently FLTX in myeloid of and studies multiple potently patients collectively between preclinical BTK targets eradication. that B-cell lux potential the including and broad both that the and lymphoma, are levels inhibits AML. studies, and precision tolerated and with of agent XXX, of milligrams dose our Xa/b XXX across has studies, been of the XXX, hematologic spectrum well generally and lux BID In often profound

exposures We new to the have of formulation reach may would to absorbed patients. this lux, in push dose better GX, of A help lux continued on promise. kind activity in that that deliver order the demonstrate of

mentioned preclinical XX-fold species the on the I’m of to has and studies, we go than depending and intro going for call, for this they they from with of are this exposures ongoing on preliminary of that at original exposure comparison. XX formulation. And the doses efficacy an original at formulation in samples drugs to have GX As A per evaluation, GX to to lux pleased PK After from been lux on we greater BID of are dose administering direct shown the the a additional our original At formulation safety collected original deliver improved dose cohort administered team, to received rapid of and report the compared look single a time, milligram strong milligrams to GX as single of patients program. PK can started XXX-milligram data collect clinical XX- we the where data available into absorption these patients. basis suggests with the that formulation. from date delivers a execution

preliminary, continue administered be to the significantly hope to a the lux a formulation We and burden our GX for advancement evaluation will pill meaningful to patients, a this sufficient the We step for drug of do amount patients. superior plan clinic. number could the and substance of reduce of to GX in GX While these determine if very truly are encouraging. data patients is of lux of

many clinic new and with from comes and And there’s preclinical always, success. to uncertainties risks. of its the formulation As models no guarantee work, translation

plan of reason, in experience in diligent details share clinic GX. dosed our with evaluation to more in with We on For we second patients enrollment our rushing being the quarter. are the and not GX this

the across and of pleased candidates, trials. dose our our tolerability ongoing are in have XXX We drug escalation progress the programs that and our lux, continued and clinical allowed safety by

to As generating we updates. treat are additional patients with forward we and data more pharmacokinetic higher pharmacologic we doses, further look that providing

please sites of that on clinicaltrials.gov. for clinical information more are ongoing recruiting For visit patients, all trials, clinical our

now Let me Rice. Dr. it turn back to Bill?

Dr. William G. Rice

Thanks, Raf.

let’s financials, a to upcoming speak our take the we milestones. look quick anticipated Before at

further which number enrolling of XXX, XXX-milligram the we expansion data dose dosing help is For greater dose expansion, go-forward well, us for we and will in expect a patients, are cohort to currently trials. determinate bring at which

As in to XXX-milligram doses Dr. XX-milligram selection at expansion the optimal and could serve expansion also to XXX-milligram capacity, our want communicate serve we Bejar of this soon. mentioned, we dose. dose And understand the dose plan the already could you if and to the

plan genetically AML also we of enriched paths. trials to communicate selection the expansion Soon, populations registration and our for

in We the these this expect to during second enriched half initiate those fixed year. dose of trials populations expansion

date we in concurrent in for June, are a to EHA and top of meeting data the with the of planning concurrent presentation with set Regarding full quarter. readout we presentation reserve plan ASH fourth line data for clinical release,

earnings Business now will past our with keep as scientific cancers financial lux, you we may well trials done Chief Financial observations to review Joti? around clinical I new as the turn similar and Chief Expect banking Dr. Joti we’ve updates GX Officer will results. the calls. and AML conferences B-cell meetings to For over our posted Officer, Marango, formulation. what on so in the the in call our and he and

Dr. Joti Marango

We into million and you, XXXX. of cash, second the equivalents Thank support good and can approximately Company which of cash the XX, half in $XX.X afternoon, ended investments, we XXXX with expect December Bill, everyone. operations

million During and XXX. XXX, purposes the to of were increased $XX activities the general in-licensing operating utilized as in cash surrounding of attributable quarter, well approximately we as activities, administrative XXX, which

ended fourth the to December $XX million We million were and XX, on for had for the income expenses for Moving quarter the the $X.X statement. XXXX. the for year. G&A were year million $XX.X of development revenues quarter the million the quarter year. and for Research expenses no $XX.X and

back Bill. share in now $XX.X EDGAR our for for on the year. SEDAR. per or More detailed $X.XX share quarter the per filings million can found To call information was will you, I or Rice. Our the million net loss $XX.X $X.XX turn and and to over be Dr.

Dr. William G. Rice

Joti. Thanks,

Operator, question. a the please please As introduce of call us. you we the open pose any if free feel first to to questions, could, question for



from line the Tenthoff Our of comes Ted from Sandler. Piper first question

Ted Tenthoff

respect with PR, that to new the response with had a question a Was I quick So, that deepening that new CRi was you XXX. a or to responder? discussed the prior

Dr. William G. Rice

Hi that, question. like patient, would please? Bejar, you Ted. on an was CRi. entirely coming add the to Thanks for that No, the new Dr. to

Dr. Rafael Bejar

the much that having reported Nothing PR. and it previously add. patients, was to is a patient more Yes, was different

Ted Tenthoff

Great. And give you more then, EHA? can the sense we respect XXX, get yet? XXX a us to be the any on it Will with data will XX, at update

Dr. William G. Rice

we and information to we’ll note, clearly, have the as you present much No the XXX-milligram Well, have to the all as at be a the completed guarantees. once But data tend XX- We we on XXX I enrollment on expansions, cohort. can by disciplined Ted, hope and very then. we enrolled fully provide this. we’ve we think

on So, to dose XX once now you not we’ve the we’ve we there, completed when provided we completed XXX we’ve up had from that information milligrams enrollment. but the gave XXX. escalation information done But in the And then, the the XX milligrams, XXX. there completed milligrams,

more are have able the a from then. because Again, to and away, give as -- that beginning of XXX-milligram it’s the cohort you we’ll have XXX, dose by we guarantees completed information We’re expansion to But not XXX. no that far number there’s release go. to patients hope the -- data emerging be on to that we information on hopefully, that and


Our the RBC of line Renza Gregory from next question Capital comes from Markets.

Unidentified Analyst

mg to questions. some profile just you. of or XXX cohort? you Wondering, color similar taking the the the provide on with the for progress. compares our how profile? expect and in have Maybe congrats Hi. around a color on Thank general that BRL qualitative we please Greg. rest cohort? the more could Maybe Should patients Thank that of for patient And you first with [Indiscernible] XXX. on

Dr. William G. Rice

continues far spoke the the that information are can genetic alterations point there MLL that a we it providing target. understand mentioned is that We we not time, that had we this the see to point and But CRi. of information hope confirmed We’ve time. all providing we’re the few any well XXX-milligram. in was Bejar to this it change at will are and that to time? and allowed confirmed. a But with add hope more this sure So, drug to over of at if these to beginning are -- about additional one patient bit CRi. Dr. other some We get this that that to -- How emerge talked want always make I or to took will time point, this these then, deepen? of in about And ask that We at others. Dr. achieved are going the the patient waited and at to the genotypes, you we’ve data Marango early the that. data us the the

Dr. Rafael Bejar

an biopsy. emphasize do MLL we in in and an patient patient MDS always patient’s you of you point And do very a at made, a AML. would just repeating the look and many a MLL-PTD, means And like And genetics additional bone I in in to the the that time very that which we remission is as waiting confirm it, disease. truly patient, co-mutations, marrow cycle, in mentioned, have Bill, take patients before declaring the they TPXX. and an the that both finding adverse of announced is abnormality included particular, adverse we mutations today, [indiscernible] had as of these and this usually

Dr. William G. Rice

important to is narrow patient we many continuing expand. clinical case, looks to believe here Yes. continues Yes. that to you. as patient development and it that’s What’s message that drugs population like more to can an treat this in more tends treat. population through Thank begin you But patients, that will it and expand, go the potential interesting treatable you is the

call So, the that’s you news us. good today. for And for thank


the from H.C. comes question next Our from Wainwright. Joe line of Pantginis

Joe Pantginis

screening I question have on lux. -- and enrollment to wanted regarding focus

How guess, that So get for or and arm any enrolling waiting it’s ask able at, to getting patients? arm might because I’m you you’re regarding both the what be way. to of this be And heard what inflection correctly, you would or is being I -- guys patients for I have first, looking have the any BID potentially you hopefully, you’re the GX if XXX-milligram GX, identify currently convoluted, find of on arm for not the I seen studies. it on And doctors change too of harder study, example. them and the study to to slope

Dr. William G. Rice

ways Joe. A respond to to of Thanks, that. Yes. couple

it very First quickly. PK heavy of is sampling, all,

the designed So, talked we’ve this. study the way -- about and is

so give a the dose then then profile. them of of milligrams. we follow on of And capsule the point, -- understand after that sampling, get GX. do hours. So, it to ambling, PK next the And XX sampling XX first first fully the the over dosing hours. milligrams PK GX, single gave hours dose of XX XX a And of they during a that dense We pharmacokinetic this the BID next we heavy single sampling original XXX XX XXX we is we a current Again, they especially that’s the milligrams. formulation the PK and dose over PK patient, of and at the go dense hours, can then

is very that. we’re actually the is stomach we that show and wanted rapid in that them and could now encouraging. to wants going we to PK every dense point it to make seeing accomplish we What undergo easier it’s formulation new this I that we sampling. absorption, clearly get rapid the have site with not But that to present this data that we yes, see what So can forward, patient think and from emulsification

And very saw what one Again, so, it’s patient. with we’re we there. happy

going be of we we still formulation. with They more ways think, bringing I can’t happy sites GX But too to they understand clinical this this new far. we dose a are. are now, GX. but but to are for the it patients have go fully take enthused, saw, to and what forward the We’re dependency new Encouraging, definitely


Our next Oppenheimer. Biegler the question of comes line from Matt from

Matt Biegler

had we’ve outside I just a the just you big see very responses thing a question for for good kind IDH. big which don’t development. picture a we thinking know is in with drug now on mentioned expanding, NPMX opportunity I market often your got of obviously current Bill, -- FLTX. here that of XXX

MLL. one there’s a in mentioned I think you new

think biggest you the opportunity where So, I’m is. just kind of curious

are have shown there’s development these, promise. of drugs for where that also Some obviously, indications in other

largest your what I’m just curious in AML. unmet of So, on Thanks. thoughts needs are kind the

Dr. William G. Rice

so This inhibitor, actually in just type exceptionally mutant the inhibits not this another we And total made FLTX, is even Hanmi kind wild able quite other forms. it very that. then these follow like we’re to the FLTX. cell. pathways the the It Sure. that -- then guacamole. of that, inhibit to drug candid. yes, effectively be and targets, Matt. these getting were FLTX interesting Thanks, certain does these fact in And we the and inhibits FLTX are does drug of inhibit it’s interested the well, and What it pathways also But

pathways, MAP but the whether of cells the pathways might You might these. done different it’s these rescue can emerge have various the metabolism, all or AKT, BCL-X it other RAS, FLTX, MCLX one kinase, all these be of

and many these around making of drug get And to a could pathways that the difficult ways it this simultaneously we many get around as was sell inhibiting drug. drug. So to to clearly see

do in more and treated different more as refractory see get the more patients going patients yes, more patients FLTX the and and are that also find you’re profiles And mutations, that So more wild and with drugs to mutation resistant over but have in years, the drugs. type. the we activity to

we this the the the of expanding you be where mutant to are the the as types treated the X next needs So, I years. the FLTX, patients. in populations to our this potential of see mentioned, as And emerge the eyes is there? in mutations? types patient the forms. seeing that for see these MLL are going are all patients looking and to beyond the are to co-mutations we’re very into What mentioned, X What various future, are And drug, adverse what

So we’re more eloquently. going very happy I’m Dr. with what Bejar we’re seeing. And to bit a say that ask to

Dr. Rafael Bejar

out mutation. not the there, are ITD, mutations tyrosine activity they a and possible think great eloquent are can target against to important and you, the I’m just mutation examples do XXX build up there domain FLTX But more of kinase inhibitors that fortunately, be kinase in for a that that. in that kinase has common target all it’s that slightly inhibitor going emerge. multiple I itself And And resistance patterns some for the only have to the Bill. of the tyrosine one in activity. and kinase both of of mechanisms points than sure FLTX different it’s I’m of you your made that And example, drugs ITD

if there I agents cause to particular So great has SYK, FLTX approved because have KIT other might or kinase the sparing mutant particular inhibitors toxicity, that target the kinases does And strongly. different those forms with slightly But have too targets shutting also pathway. the ability JAK think treated that a we’re inhibited profile. off they I that while are just think were out it patients be and also been to it hit, of that more previously to pattern,

that allow in. So to great refractory have opportunity we we agents we but a other same will I And think like medical patient go traditional just by if the patient route we treated that the have something I need population us a not might that frontline clinic those have of are have get become to that. populations populations really activity in to agents, unmet that an that’s or than more had sooner think

Dr. William G. Rice

very important point. a Yes. That’s

see populations, build that also Let to patients me forward to drug in other have the the -- toward move wild accelerated quickly you since done have to with we forward already the populations medical we parallel as you those Well, then identify we unmet activity look FLTX to patients pathways. approval to in approval, we’ve We drive later. that so type the be because high in already rapid drug begin go means But want unmet and the just very testing you be expand several those need, that. and hope need. that see able but out to this hope label and can toward we accelerated the that to medical would approvals, that on

XXX. hope that our I So, question. your answers with plans those are

Matt Biegler

wild Yes. That makes if sense. the at mutant, or can But, I Maybe if if I could they just complete squeeze were in confirm type? you FLTX was a apologize responder quick FLTX XXX a a follow-up. this. missed new I

Dr. William G. Rice

yet. that We released haven’t information

we’re what to drug release proves up at it and So, we’ll all when at go this population. coming levels soon. active going back dose to is a is that But does, information. look way, take have EHA either multiple and it the expands out

So we’ve thrilled either with what seen. we’re way,


Our Soumit next from comes line Roy question Jones Research. from of the

Soumit Roy

Hi. the that are patients too. in to CR cell of the understand Congratulations on into Trying be progressing would -- are stem future, from transplantation. what Great me, most detail.

transplantation? how So, think where going this months were is setting? to and at looking X to relapsed/refractory these of eligible you’re the patients transplant you about to they in paradigm going be Is that become DOR X and

Dr. William G. Rice

Yes, please.

Dr. Rafael Bejar

can jump I in here.

of more we it option. predicted. have [ph] the midostaurin speaks stage of activity feasible into a many this that where transplantation a absolutely into transplant the that to would patients issue And actually than right trial a the going a for get of in seen You’re an even they allows part, to drug becomes cell the pattern is patients have And where were stem the that. RATIFY in

So, to a as I’m clinician, see that. thrilled

be a treat we our we if such disease that doing to could that patients a potentially curative that. should think I terrible offer procedure

by encouraged that I’m So, activity.

positive. a it’s think I

However, as not have patient that every an option. will

risk. with the -- that on don’t transplant cell life. patient condition predicted, that a for a relapsed/refractory very have had donor a year patient to that improve profile a to one And was do have of for we you can single isn’t a over of that them. and that a have where had ineligible So in oral relapse durable AML. stem who would these daily transplant early responses duration agent their they did was And oral have [indiscernible] life sense want quality either We a they for transplant the agents makes or greatly patients really are have

So, need duration in we cycles. a response activity is never to very to seeing what patients the patient was I when be, X really by X we likely and upset but I that or experience to of more more understand there. get transplant encouraged And

Dr. William G. Rice

great It’s point. Yes. a

So ineligible transplant. we drug want we’re looking the really, the But see as are for durable is to that patients in for here. yes, survival what

of these mission. to can our the survival So do enhance patients, that’s we anything that

Soumit Roy


would So, at in transplantation MRD terms into then come a could or get include now on do trial? complementary rate you OS would firsthand do response transplantation, you as it of confirmatory the the survival, approval status would based a that? trial, looked think How accelerated negative and effect or or which be envision

Dr. William G. Rice

agency, Dr. the address would But one, with have too? FDA. like will that we the conversations be you Bejar, to will Those

Dr. Rafael Bejar

for it improve mean say patients a were that those survival And patients overall on unfortunately, with short in unmet in would need. that down ultimately, I treated but might FDA approval special I population patient the OS. precedence those the they confirmatory survival, has trial, wasn’t overall have based either. there their in to that certainly have point even regard I think endpoints overall fit need, for end that trial And improve a the road, populations short to for patient them the will this cure Yes. that paying those -- survival. medical is so and populations surrogate getting considers important attention that are the of in we

here. of we help patients have lot So, that certainly a we can

Dr. William G. Rice

an there. a drug? activity Yes. we’re see is news this active The is not good there’s question, asking We

about talking now the getting for approval. actually endpoints We’re what are

tells So, come quickly you very how that far this drug. just we’ve with


Thank you.

We have question. time for one further

the today for Global line Partners. question comes Allegiance Cross final Our of Matthew from from

Matthew Cross

Hey, guys. for for Good CR new me as the afternoon. Congrats on XXX well.

if PK question that can sampling skip is these kind you of X-part the near of towards far, current PK XX-milligram while commented kind or there can kind in the if you any kind when curious, of moving this Thanks. GX envision to kind so of that in curious keeping sampling kind time, may continue pausing I’ll GX the and I the of know of would a in that just GX, related study two-parter are lux. of what so sake same on GX, dose answer explored moving For that I of something midyear. kind do you was we assume, was -- patients PK to something seen that, to lux. I GX and now in exposure expect or you’re that housekeeping XXX-milligram kind don’t terms But escalating is, you’ve GX I GX? of but guide see of Bill, on exploring ask the And into a the I question, XXX-milligram you’ve now, for and equivalency GX on from dose you what’s will right focus for at time? going with at lux the of the or you

Dr. William G. Rice

limited Well, have again with are questions that we What that in -- did the we speaking absorption a is GX. there I’ll I of about there never GX, rise say with we’re seen rapid are Because cautious. see data Matt, the can there. few be

with even the to dose. the And system. exposure that hours, see up were solubilized that one while a GX GX. that we there in it to clearly comparing being XX-milligram we very XX-fold the again, could some with data. And we XX left there Again, we And limited being were saw was well. drug milligrams, of was absorbed happy So, dose more of XXX

we going get if we if continue understand the or whether to any to don’t now we we that’s But saw. need profile escalate. And were so, And exposure to we continue. know with pleased dose we that yes, not

So, don’t know. with but we just saw, what we enthused we’re

in going of milligrams. then Now, we’re the GX, dosing XXX currently, patients, collecting forward, the they those terms and data get

we of us able BID of tell and we patients and year we collect that compare with and then have additional to are we’ll modeling But the future believe, as to are future be data. a XXX that that enough toward patients GX goes exposures then And a go that allows the deal near transition at exposure be milligrams not be the do only. a can us the hopefully, to on then, a going us treated PK hopefully the milligrams GX -- lot on continuous gives the whether grams BID. to that X.X patient day, on to levels. That here, the or GX envision the dose over to the dosing truly XXX actually great into of to That’s going we GX, So, into thereafter. data depends

us go question, will Did data the that can in answer but provide hopeful, continue data Matt? as we to that forward. guide the will we as We’re your as much we direction. And

Matthew Cross

does middle a I it going. the more now, Bill. Yes, look of Understood. I’ll year. few it answers to forward for keep

Dr. William G. Rice

right. you Looking Thanks, All to showing graphs. Matt. the forward


question-and-answer This program the of to session the for conclude you. program. I’d Dr. like Thank back hand does William any Rice today’s to remarks. further

Dr. William G. Rice

bring shareholders. to to keep commitment that this remarkable I’ll the I are Company for this us to want afternoon. joining short. as thank really significant lux and everyone our We for XXX And just want to part will Well, effort. We grateful believe that as proud really our assets Aptose well this both the value for be and the dedication serve. team their to thank the and to I’m of employees patients we and

and look pipeline clinical updating shareholders exciting all of investigators. existing more for days. in our on you pipeline and forward grateful also to do we And our the our We’re coming

evening. thank a everyone. wonderful So, you, Have


ladies and gentlemen. you, conference. today’s concludes That Thank

wonderful all a may have disconnect, day. and You